Skip Navigation LinksHome > April 2014 - Volume 21 - Issue 2 > Human β-cell regeneration: progress, hurdles, and controver...
Current Opinion in Endocrinology, Diabetes & Obesity:
doi: 10.1097/MED.0000000000000042
DIABETES AND THE ENDOCRINE PANCREAS I: Edited by David M. Harlan

Human β-cell regeneration: progress, hurdles, and controversy

Jurczyk, Agata; Bortell, Rita; Alonso, Laura C.

Collapse Box

Abstract

Purpose of review: Therapies that increase functional β-cell mass may be the best long-term treatment for diabetes. Significant resources are devoted toward this goal, and progress is occurring at a rapid pace. Here, we summarize recent advances relevant to human β-cell regeneration.

Recent findings: New β-cells arise from proliferation of pre-existing β-cells or transdifferentiation from other cell types. In addition, dedifferentiated β-cells may populate islets in diabetes, possibly representing a pool of cells that could redifferentiate into functional β-cells. Advances in finding strategies to drive β-cell proliferation include new insight into proproliferative factors, both circulating and local, and elements intrinsic to the β-cell, such as cell cycle machinery and regulation of gene expression through epigenetic modification and noncoding RNAs. Controversy continues in the arena of generation of β-cells by transdifferentiation from exocrine, ductal, and alpha cells, with studies producing both supporting and opposing data. Progress has been made in redifferentiation of β-cells that have lost expression of β-cell markers.

Summary: Although significant progress has been made, and promising avenues exist, more work is needed to achieve the goal of β-cell regeneration as a treatment for diabetes.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.